EURACTIV - Over the next decade, a wave of biologic medicines will lose patent protection in Europe, but unlike the past ten years, biosimilar competition and the savings and access it brought are no longer guaranteed to follow. Read more
Nicole Verbeeck is an independent health journalist covering health and life sciences in Europe. Alongside her reporting, she leads an editorial studio specializing in journalism, editorial work and creative editorial formats.
Independent journalism
Reporting on health and life sciences in Europe for:
Euractiv (Advocacy Lab)
EU Perspectives
European Biotechnology Magazine
APM Market Access
Editorial studio in health & life sciences
Creative editorial projects
Latest articles
EU PERSPECTIVES - The biggest overhaul of Europe's pharmaceutical law in two decades is to arrive this autumn, with a two-year transition. Lawyer Hein van den Bos explains to EU Perspectives what changes, what the debate missed, and why anything now in development is already affected. Read more
EURACTIV - Belgium does not spend unusually little on medicines compared with its larger neighbours. It spends the money badly, argues Professor Walter Van Dyck. The economist says Belgium cuts prices hard to stay within a tight budget today, then pays later in lost innovation. Read more
EU PERSPECTIVES - New medicines are reaching Europe later than the US. A recent study says two separate policies are to blame, and that the damage is the worst when they meet. Read more
